Rezon Bio is a next-generation contract development and manufacturing organisation (CDMO) dedicated to biologics. Headquartered in Poland, the company supports clients from cell line development through to commercial production, combining in-house capabilities in analytics, process development, technology transfer and GMP manufacturing. With mirrored facility capabilities in Gdańsk and Warsaw-Duchnice and a focus on quality, efficiency and digital transparency, Rezon Bio enables biopharma companies to scale from concept to market with confidence.

The firm positions itself as “Driven by science. Powered by partnerships,” emphasising that its integrated services and full-scale manufacturing platform reduce complexity for clients while maintaining regulatory readiness. Its offering spans development, analytical characterisation, manufacturing and quality systems, all backed by over 16 years of experience and a team of around 1,300 professionals with diverse global expertise.

Key products and services

• Process development & characterisation for biologic drug substances.
• Analytical capabilities including method-qualified testing and product release.
• GMP manufacturing of biologics (commercial scale, single-use bioreactors and mirrored site architecture).
• Technology transfer, MSAT (Manufacturing Science & Technology) and PPQ (Process Performance Qualification).
• End-to-end CDMO services from early development through to commercial supply.
• Quality systems aligned with global regulatory expectations, including FDA and EMA audits.

Rezon Bio combines European biopharma talent, mirrored facility infrastructure and a digital-enabled service model to deliver biologics CDMO solutions. As clients seek scalable, compliant and efficient manufacturing paths, the company’s integrated platform offers a tailored route from development to commercialisation. Whether advancing novel biologics or transitioning to market supply, Rezon Bio aims to provide a robust partner for biopharma companies navigating the biologics lifecycle.